RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @DrWillWatson: https://t.co/uWwqCqyntt Interesting but ignores the contributions of cardiac metabolism to obesity-related HFpEF. Of cou…
RT @DrWillWatson: https://t.co/uWwqCqyntt Interesting but ignores the contributions of cardiac metabolism to obesity-related HFpEF. Of cou…
https://t.co/uWwqCqyntt Interesting but ignores the contributions of cardiac metabolism to obesity-related HFpEF. Of course there is one treatment for obesity related heart disease that really works... @JACCJournals #cardioed https://t.co/E7sK1St6Ip
TRIADA INTERESANTE en el manejo de la HFpEF + Obesidad : Inhibidores de Aldosterona , Neprelisina, ISGLT2 . #InsuficienciaCardiaca https://t.co/fVJPvNwEya https://t.co/CxkO5Lh5MX
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @AtulPathak31: The new heart failure paradigm after digitalis ans diuretics , after RAS and beta blockers the future triple therapy?.@A…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @AtulPathak31: The new heart failure paradigm after digitalis ans diuretics , after RAS and beta blockers the future triple therapy?.@A…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @AtulPathak31: The new heart failure paradigm after digitalis ans diuretics , after RAS and beta blockers the future triple therapy?.@A…
The new heart failure paradigm after digitalis ans diuretics , after RAS and beta blockers the future triple therapy?.@AnastasiaSMihai @AngoulvantD @SABOURETCardio @CNCFCardio @escardio @PCRonline @ESH_Annual @ThibaudDamy @Giccardio_fr @roubille @echoralj
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
Obesity-Related Heart Failure With a Preserved Ejection Fraction https://t.co/ITrGkKPxyo
RT @coconnormd: JACC-HF special HFpEF edition SOA : Obesity and HFpEF pathophysiological linkage and targeted therapies https://t.co/hlDFy…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @coconnormd: JACC-HF special HFpEF edition SOA : Obesity and HFpEF pathophysiological linkage and targeted therapies https://t.co/hlDFy…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
RT @ValleAlfonso: The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in c…
The promise of using 1️⃣mineralocorticoid antagonists, 2️⃣neprilysin inhibitors, and 3️⃣SGLT2 inhibitors (alone or in combination) inthe management of obesity-related HFpEF vía @JACCJournals 📎 https://t.co/yPIa3wGKQv https://t.co/Xks6SpYBNj
RT @coconnormd: JACC-HF special HFpEF edition SOA : Obesity and HFpEF pathophysiological linkage and targeted therapies https://t.co/hlDFy…
RT @coconnormd: JACC-HF special HFpEF edition SOA : Obesity and HFpEF pathophysiological linkage and targeted therapies https://t.co/hlDFy…
JACC-HF special HFpEF edition SOA : Obesity and HFpEF pathophysiological linkage and targeted therapies https://t.co/hlDFyA2724
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
Its sounds good 👌 https://t.co/s28nIw1rrm
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
RT @paolabel_cardio: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Fai…
The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, & i SGLT-2 in Obesity-Related Heart Failure With Preserved EF. Might finally have a phenotype of HFpEF that we can understand and treat.https://t.co/XTSLOlFr5k https://t.co/
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
RT @mendez_bailon: Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y nepril…
Revision de #obesidad en #IC preservada que propone futuras díanas terapéuticas :bloqueo de aldosterona, SGLT2 y neprilisina. La combinación empagliflocina+/-sacubitril/valsartan+/- aldactone puede ser interesante pero necesitamos ensayos https://t.co/vCU
RT @Paddy_Barrett: While more therapies are desperately needed for HFpEF, the utilization of 3 separate drugs to treat obesity related HFpE…
Nice review of obesity associated Heart Failure https://t.co/iNLVRyJfJo
RT @Paddy_Barrett: While more therapies are desperately needed for HFpEF, the utilization of 3 separate drugs to treat obesity related HFpE…
While more therapies are desperately needed for HFpEF, the utilization of 3 separate drugs to treat obesity related HFpEF is hard to accept given that an equally if not more effective measure is weight loss https://t.co/AJq7ytKRMe